BTK and NLRP3 being expressed in different cells involved in the pathogenesis of kidney injuries (i.e., epithelial cells, macrophages and B-cells), we put forward the hypothesis that ibrutinib may prevent AKI or transition from AKI to CKD by targeting immune and tubular cells. This evidence concerns the gene BTK and chronic kidney disease.